Bristol-Myers Squibb (NYSE:BMY), a global biopharmaceutical company with a market capitalization of nearly $120 billion, finds itself at a critical juncture as it navigates a complex landscape of ...

The Centers for Medicare and Medicaid Services (CMS) says about 8,247,000 people with Medicare Part D coverage use the ten drugs selected for price negotiation.

Bristol is also still looking for deals to find new sources of growth with top-sellers like Revlimid, Opdivo and Eliquis either facing or about to face generic competition. “We don’t sit there ...

The drug and biotech industry had a tough time in the past couple of months after Trump announced the appointment of Robert F. Kennedy Jr., a vaccine skeptic, as the head of Health and Human ...

Substance abuse in the United States is one of the leading health conditions impacting millions of lives and due to many types of drug addictions. Since 2000, there have been 700,000 overdose deaths ...

This along with the current drug shortage will support the revenue ... sold under the brand name Keytruda by Merck and Co., Eliquis (Apixaban) sold by Bristol Myers Squibb and Pfizer, Eylea ...